Within the span of 19 hours, weight loss drugmakers Novo Nordisk and Eli Lilly offered wildly divergent views on where business is headed. https://t.co/6KjPqHNuqm ...

MATT: I MATT MILLER. DANI: I'M DANI BURGER. "BLOOMBERG OPEN INTEREST" STARTS RIGHT NOW.FEARS OF AI DISRUPTION RIPPLE THROUGH MARKETS, HITTING SOFTWARE MAKERS AND AD AGENCIES, AS WELL AS FINANCE AND INVESTMENT FIRMS. DANI: DIVERGENCE IN PHARMA, ELI LILLY, SURGING SALES. NOVO NORDISK, STEEP DECLINE.MATT: FROM SANTANDER AIR TO NVIDIA, DEALMAKING IS BACK AT OF THE DEBUT OF DANI'S NEW SHOW, "BLOOMBERG DEALS." DANI: I DIDN'T KNOW WE WERE GOING TO DO THAT AT THE TOP OF THE SHOW. THANK YOU, MATT. I'M LOOKING FORWAR ...

At Cash Flow Club , we focus on businesses with strong cash generation, ideally with a wide moat and significant durability. When these companies are bought at the right time, that can be highly rewarding for us. If you are interested in joining our community, start right here !Novo Nordisk A/S ( NVO ) reported its earnings results on Tuesday, with those results being more or less in line with expectations. Novo Nordisk's guidance for the current year, however, was weaker than whatJonathan Weber holds an en ...

♪ NOW, UBS HAS ANNOUNCED A $3 BILLION BUYBACK ALONGSIDE WHAT ANALYSTS ARE DESCRIBING AS A MIX RESULTS. $1.2% BILLION BEAT EXPECTATIONS BUT IN FLOWS AT THE KEY WEALTH MANAGEMENT SLUMPED AND I’VE BEEN SPEAKING WITH THE CHIEF EXECUTIVE. >> THE MARKET IS BROADLY CONSTRUCTIVE, IF YOU LOOK AT THE ECONOMIC OUTLOOK AND LOOK AT THE INVESTMENTS GOING THROUGH THE ECONOMIES IN THE U.S. AND YEARS OF TECHNOLOGY, INFRASTRUCTURE, ENERGY, IT’S GOING TO BE QUITE CONSTRUCTIVE FOR THE ECONOMY AND THEREFORE WE SEE MARKETS, BROA ...

Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. ...

In 2025, I bought every crash of Novo Nordisk A/S ( NVO ) stock and it rapidly became one of my top picks. My recent articles always presented a Strong Buy rating, but this onePassionate about geopolitics and macroeconomics, I express my opinion through my articles and enjoy engaging with all of you. I also write about companies that catch my attention, particularly those in my portfolio. For me, Seeking Alpha is a way to expand my knowledge and therefore become a better investor.Analyst’s Disclosure: I/we ...

Core Viewpoint - Novo Nordisk A/S is experiencing significant stock declines due to a weak sales forecast despite beating fourth-quarter earnings and revenue estimates, with the company citing "unprecedented" price pressures from competition in the weight-loss drug market and potential drug cost cuts by President Trump [1] Group 1: Stock Performance - Novo Nordisk's stock is down 3.7% to $48.44, extending a previous 14.6% decline, and is now at its lowest levels since December [1][2] - The stock has decreased by 41.4% year over year [2] Group 2: Market Activity - Options trading shows increased bullish sentiment, with 56,000 calls exchanged today, which is double the typical volume, compared to 27,000 puts [2] - The March 45 put is noted as the most active contract [2] Group 3: Options Trading Trends - Over the past 10 weeks, calls have been more popular than usual, with a 50-day call/put volume ratio of 4.59, ranking higher than 97% of readings from the past year [3] - Novo Nordisk stock has historically outperformed options traders' volatility expectations, reflected in a Schaeffer's Volatility Scorecard (SVS) of 89 out of 100 [3]

Key Takeaways NVO shares slumped 15% after a conservative outlook pointed to a 5-13% sales decline in 2026. Novo Nordisk cited U.S. pricing pressure and semaglutide patent expiries as key drags. NVO highlighted new U.S. leadership and wider Wegovy rollout, boosting appeal of diversified ETFs. Shares of Danish drugmaker Novo Nordisk (NVO) suffered a sharp slump of 15% on the bourses on Tuesday, after the company issued a conservative sales outlook that implied a 5-13% decline in 2026 from last year. This new ...

Core Insights - Novo Nordisk A/S reported adjusted fourth-quarter 2025 earnings of $1 per ADR, exceeding the Zacks Consensus Estimate of 90 cents, but down from $0.98 per ADR in the same quarter last year [2][4] - Revenues for the quarter were $12.34 billion, an 8% decline year over year in DKK and a 2% decline at constant exchange rates, primarily due to lower-than-expected sales in Diabetes and Obesity Care [3][4] - Despite beating earnings estimates, Novo Nordisk's shares fell 14.6% as investors reacted negatively to the company's poor sales and operating profit outlook for 2026 [4][9] Financial Performance - The Diabetes and Obesity Care segment reported sales of DKK 73.8 billion, a 2% decline, with notable changes in product sales: Fiasp up 154%, NovoRapid down 24%, and Human insulin down 24% [6] - Ozempic sales were DKK 31.83 billion, up 1%, while Rybelsus sales fell 19% to DKK 5.30 billion [7] - Obesity Care sales increased 11% to DKK 22.45 billion, with Wegovy's sales growth slowing to 17% due to competition and illegal market versions [8] 2026 Outlook - Novo Nordisk expects adjusted sales and operating profit to decline by 5-13% at constant exchange rates in 2026, with further declines expected when translated into DKK due to adverse FX movements [9][17] - The guidance indicates a potential negative sales growth of -1% and modest operating profit growth of 11%, highlighting reliance on non-recurring accounting benefits [17][21] - The company faces challenges from slowing prescription trends, increased competition, and pricing pressures, particularly in the U.S. market [18][21] Competitive Landscape - Eli Lilly is gaining market share in diabetes and obesity, raising concerns about Novo Nordisk's ability to maintain its competitive edge [22] - The launch of oral Wegovy is seen as a potential differentiator, but historical trends suggest that late entrants can still dominate the market [22] Investment Sentiment - The market reaction reflects investor disappointment with the slowing core momentum in diabetes and obesity franchises, ongoing pricing pressures, and rising investment intensity [20][21] - Novo Nordisk's stock is currently rated Zacks Rank 4 (Sell), indicating a cautious outlook among analysts [23]

when you of course get a pricing headwind on your GLP1 products VGOI and OMIC you feel the pressure of that more but um but also on the back of of course being a focused company and being the best in what we do we feel very confident that the volume buildup will happen um script by script and we have seen the early signals of that with our Vigovi pill launch so I'm very hopeful that while we're disappointing the investors today on a short-term price decrease they will be quite Happy to see that we will be a ...